• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    11/14/24 7:59:55 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COGT alert in real time by email
    SC 13G/A 1 p24-3394sc13ga.htm COGENT BIOSCIENCES, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    Cogent Biosciences, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    19240Q201

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 19240Q20113G/APage 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    15,116,496 shares of Common Stock (including 4,516,000 shares of Common Stock issuable upon conversion of Preferred Stock)* (see Item 4)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    15,116,496 shares of Common Stock (including 4,516,000 shares of Common Stock issuable upon conversion of Preferred Stock)* (see Item 4)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    15,116,496 shares of Common Stock (including 4,516,000 shares of Common Stock issuable upon conversion of Preferred Stock)* (see Item 4)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9%* (see Item 4)

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    *As more fully described in Item 4, certain of the Series B Non-Voting Preferred Stock (the “Preferred Stock”) are subject to a 9.99% blocker (the “9.99% Blocker”), and the percentage set forth in row (11) gives effect to such 9.99% Blocker. However, as more fully described in Item 4, the shares of Common Stock reported as being issuable upon conversion of the Preferred Stock in rows (6), (8) and (9) include the number of shares of Common Stock that would be issuable upon full conversion of the Preferred Stock and does not give effect to such 9.99% Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such 9.99% Blocker, is less than the number of shares of Common Stock reported in rows (6), (8) and (9) to be issuable upon conversion of the Preferred Stock.

     

    CUSIP No. 19240Q20113G/APage 3 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    15,116,496 shares of Common Stock (including 4,516,000 shares of Common Stock issuable upon conversion of Preferred Stock)* (see Item 4)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    15,116,496 shares of Common Stock (including 4,516,000 shares of Common Stock issuable upon conversion of Preferred Stock)* (see Item 4)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    15,116,496 shares of Common Stock (including 4,516,000 shares of Common Stock issuable upon conversion of Preferred Stock)* (see Item 4)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9%* (see Item 4)

    12

    TYPE OF REPORTING PERSON

    CO

             

     

    *As more fully described in Item 4, certain of the Preferred Stock are subject to a 9.99% Blocker, and the percentage set forth in row (11) gives effect to such 9.99% Blocker. However, as more fully described in Item 4, the shares of Common Stock reported as being issuable upon conversion of the Preferred Stock in rows (6), (8) and (9) include the number of shares of Common Stock that would be issuable upon full conversion of the Preferred Stock and does not give effect to such 9.99% Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such 9.99% Blocker, is less than the number of shares of Common Stock reported in rows (6), (8) and (9) to be issuable upon conversion of the Preferred Stock.

     

    CUSIP No. 19240Q20113G/APage 4 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Cubist Systematic Strategies, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 19240Q20113G/APage 5 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    15,116,496 shares of Common Stock (including 4,516,000 shares of Common Stock issuable upon conversion of Preferred Stock)* (see Item 4)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    15,116,496 shares of Common Stock (including 4,516,000 shares of Common Stock issuable upon conversion of Preferred Stock)* (see Item 4)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    15,116,496 shares of Common Stock (including 4,516,000 shares of Common Stock issuable upon conversion of Preferred Stock)* (see Item 4)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9%* (see Item 4)

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    *As more fully described in Item 4, certain of the Preferred Stock are subject to a 9.99% Blocker, and the percentage set forth in row (11) gives effect to such 9.99% Blocker. However, as more fully described in Item 4, the shares of Common Stock reported as being issuable upon conversion of the Preferred Stock in rows (6), (8) and (9) include the number of shares of Common Stock that would be issuable upon full conversion of the Preferred Stock and does not give effect to such 9.99% Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such 9.99% Blocker, is less than the number of shares of Common Stock reported in rows (6), (8) and (9) to be issuable upon conversion of the Preferred Stock.

     

    CUSIP No. 19240Q20113G/APage 6 of 8 Pages

     

    Item 1(a). Name of Issuer:
      Cogent Biosciences, Inc. (the “Issuer”).
       
    Item 1(b). Address of Issuer's Principal Executive Offices:
      275 Wyman Street, 3rd floor, Waltham, Massachusetts 02451.
       
    Item 2(a). Name of Person Filing:
      This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.001 per share (“Common Stock”), of the Issuer held by (and shares of Common Stock underlying the Preferred Stock held by) Point72 Associates, LLC, an investment fund it manages (“Point72 Associates”); (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to shares of Common Stock held by (and shares of Common Stock underlying the Preferred Stock held by) Point72 Associates; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic Strategies”) with respect to shares of Common Stock that were held by an investment fund it manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to shares of Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc., and shares of Common Stock that were beneficially owned by Cubist Systematic Strategies.
       
      Cubist Systematic Strategies, an advisor under common control with Point72 Asset Management, acts as a sub-advisor with respect to a portion of the shares of Common Stock reported herein.
       
    Item 2(b). Address of Principal Business Office:
      The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.
       
    Item 2(c). Place of Organization:
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.  Mr. Cohen is a United States citizen.
       
    Item 2(d). Title of Class of Securities:
      Common Stock, par value $0.001 per share.
       
    Item 2(e). CUSIP Number:
      19240Q201
       
    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.
       

     

    CUSIP No. 19240Q20113G/APage 7 of 8 Pages

     

     

    Item 4. Ownership:
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on September 30, 2024.

     

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

     

    Certain of the Preferred Stock reflected on the cover pages are subject to a 9.99% Blocker whereby they are not convertible to the extent that following such conversion, taking into account all other shares of Common Stock beneficially owned by the Reporting Persons, the Reporting Persons would beneficially own in excess of 9.99% of the Issuer’s outstanding Common Stock, as calculated in a manner consistent with the provisions of Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. Consequently, as of the date of the event which requires the filing of this statement, some of the Preferred Stock referred to herein are not presently convertible due to the 9.99% Blocker.

       
    Item 5. Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [  ].
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
      Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding shares of Common Stock.  
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group:
      Not applicable.
       
    Item 9. Notice of Dissolution of Group:
      Not applicable.
       
    Item 10. Certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         

     

     

    CUSIP No. 19240Q20113G/APage 8 of 8 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
     

    Title:    Authorized Person

     

     

      POINT72 CAPITAL ADVISORS, INC.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

      CUBIST SYSTEMATIC STRATEGIES, LLC
       
      By:  /s/ Jason M. Colombo
     

    Name:  Jason M. Colombo

    Title:    Authorized Person

       
      STEVEN A. COHEN
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       

     

     

    Get the next $COGT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COGT

    DatePrice TargetRatingAnalyst
    3/7/2025$17.00Sector Outperform
    Scotiabank
    12/11/2024Buy → Hold
    Needham
    2/26/2024$14.00 → $8.00Outperform → Neutral
    Robert W. Baird
    2/8/2024$11.00Buy
    Citigroup
    12/11/2023$5.00Outperform → Neutral
    Wedbush
    12/8/2023$18.00Overweight
    JP Morgan
    4/28/2023$20.00Outperform
    Robert W. Baird
    3/27/2023$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $COGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ferrante Karen Jean

      4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

      4/3/25 4:05:21 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Green John L.

      4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

      1/27/25 5:03:58 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Pinnow Cole

      4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

      1/27/25 5:00:07 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Cogent Biosciences with a new price target

      Scotiabank initiated coverage of Cogent Biosciences with a rating of Sector Outperform and set a new price target of $17.00

      3/7/25 8:04:46 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences downgraded by Needham

      Needham downgraded Cogent Biosciences from Buy to Hold

      12/11/24 7:28:07 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Cogent Biosciences from Outperform to Neutral and set a new price target of $8.00 from $14.00 previously

      2/26/24 7:27:30 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cogent Biosciences Reports First Quarter 2025 Financial Results

      Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million in cash, sufficient to fund operations into late 2026 WALTHAM, Mass. and BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 was very productive for Cogent

      5/6/25 8:00:00 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

      WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer Research (AACR) 2025 Annual Meeting taking place in Chicago. "We welcome the opportunity to present updated results from these programs that represent our exciting pipeline of potential best-in-class targeted therapies," said Andrew Robbins, Cogent's President and Chief Executive Officer. "These data demonstrate Cogent's ability to discover and advance novel the

      4/25/25 8:08:47 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

      WALTHAM, Mass. and BOULDER, Colo., March 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced four preclinical poster presentations at the upcoming 2025 AACR Annual Meeting being held in Chicago, IL April 25-30, 2025. Poster Details Title: Identification of a potent KRAS (ON) inhibitor with selectivity for mutant KRAS over HRAS and NRASSession Category: ChemistrySession Title: Lead Identification and OptimizationSession Date and Time: April 30, 2025 - 9:00 AM – 12:00 PM CT (10:00 AM – 1:00 PM ET)Location: Poster Section 25Poster Board Number: 3Published Abst

      3/25/25 4:31:00 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Financials

    Live finance-specific insights

    See more
    • Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting

      WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced upcoming presentations for bezuclastinib at the 64th Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, LA from December 10-13, 2022. The company will also host a virtual investor event on December 12 that will be accessible via conference call and webcast, with full details to be made available closer to the date. Oral presentation details: Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Nov

      11/3/22 9:05:00 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

      All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment All bone marrow biopsy-assessed patients achieved ≥50% bone marrow mast cell reduction and decreases in blood KIT D816V variant allele fraction (VAF) Bezuclastinib demonstrates favorable initial safety and tolerability profile with no reported periorbital or peripheral edema, cognitive effects or intracranial bleeding events  Cogent to host investor conference call and webcast today at 8:00 a.m. ET  CAMBRIDGE, Mass. and BOULDER, Colo., June 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biote

      6/10/22 7:00:00 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    SEC Filings

    See more
    • SEC Form EFFECT filed by Cogent Biosciences Inc.

      EFFECT - Cogent Biosciences, Inc. (0001622229) (Filer)

      5/12/25 12:15:02 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cogent Biosciences Inc.

      10-Q - Cogent Biosciences, Inc. (0001622229) (Filer)

      5/6/25 9:00:20 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cogent Biosciences, Inc. (0001622229) (Filer)

      5/6/25 8:19:30 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

      SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

      11/14/24 7:59:55 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

      SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

      11/14/24 5:47:15 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

      SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

      11/14/24 4:05:10 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Pinnow Cole bought $332,412 worth of shares (43,750 units at $7.60), increasing direct ownership by 2,085% to 45,848 units (SEC Form 4)

      4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

      1/15/25 7:00:04 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COGT
    Leadership Updates

    Live Leadership Updates

    See more
    • Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

      WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients

      5/23/24 5:05:00 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development

      WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Rachael Easton, MD, Ph.D., Vice President, Head of Clinical Development. "We are pleased to welcome Dr. Easton to Cogent as we continue to develop bezuclastinib in Systemic Mastocytosis and GIST," said Andrew Robbins, the company's President and Chief Executive Officer. "Dr. Easton is an accomplished physician-scientist who brings a wealth of experience in both early and late-stage clinical development across multiple therapeutic areas. Her backgrou

      11/28/22 4:15:00 PM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer

      CAMBRIDGE, Mass. and BOULDER, Colo., May 3, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Evan Kearns as Chief Legal Officer. In his new role, Mr. Kearns will oversee all corporate legal operations for Cogent Biosciences. "I am excited to welcome Evan to the Cogent team as our Chief Legal Officer," said Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences. "Evan's expert counsel and proven leadership in ad

      5/3/21 7:00:00 AM ET
      $COGT
      Biotechnology: Pharmaceutical Preparations
      Health Care